| Reactivity | MuSpecies Glossary |
| Applications | Bioactivity |
| Format | Carrier-Free |
| Details of Functionality | Measured by its ability to inhibit TGF-beta 2 activity on HT‑2 mouse T cells. Tsang, M. et al. (1995) Cytokine 7:389. The ED50 for this effect is 8-40 ng/mL in the presence of 1 ng/mL of rhTGF-beta 2. |
| Source | Mouse myeloma cell line, NS0-derived mouse TGF-beta RIII protein Gly23-Thr785, with a C-terminal 6-His tag |
| Accession # | |
| N-terminal Sequence | Gly23 |
| Protein/Peptide Type | Recombinant Proteins |
| Gene | Tgfbr3 |
| Purity | >90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| Endotoxin Note | <0.10 EU per 1 μg of the protein by the LAL method. |
| Dilutions |
|
|
| Theoretical MW | 85.6 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| SDS-PAGE | 105-115 kDa, reducing conditions |
|
| Publications |
|
| Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
| Buffer | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Purity | >90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| Reconstitution Instructions | Reconstitute at 100 μg/mL in sterile PBS. |
Transforming growth factor beta receptor III (TGF-beta RIII; also betaglycan) is a ubiquitously expressed, 280 kDa type I transmembrane proteoglycan member of the TGF-beta superfamily of proteins (1). Mouse TGF-beta RIII is synthesized as an 850 amino acid (aa) precursor that consists of a 22 aa signal sequence, a 763 extracellular domain (ECD), a 23 aa transmembrane region, and a 42 aa cytoplasmic tail (SwissProt # O88393). The large ECD contains heparan sulfate and chondroitin sulfate glycosaminoglycans, five potential N-linked glycosylation sites, and a zona pellucida-like domain from residues 454 - 731 (1 - 2). The short cytoplasmic domain is rich in serine and threonine, but has no discernible signaling structure typical of receptor kinases (2). Proteolysis at one of two potential juxtamembrane cleavage sites (Lys743Lys and Leu750AlaValVal) allows cells to release TGF-beta RIII in a soluble form (1 - 2). Mouse TGF beta RIII shares 94%, 82%, 80%, and 67% aa sequence identity with rat, human, porcine, and chicken TGF-beta RIII, respectively (2). In all of these species, TGF beta RIII contains 17 cysteines that are 100% conserved (2). TGF-beta RIII binds with high affinity to TGF-beta 1, TGF-beta 2, and TGF-beta 3 isoforms (1). TGF-beta RIII functions by binding, and then "presenting" ligand to TGF-beta type II receptors (1, 3). It also functions to limit ligand availability to the receptor via proteolysis which releases the soluble form of TGF beta RIII along with any bound factors, making them inaccessible to cell-surface receptors (1, 3). TGF-beta RIII can therefore enhance or inhibit cell signaling. TGF-beta RIII has been shown to play an essential role in the formation of the atrioventricular cushion and coronary vessels during development of the heart (4 - 6). TGF beta RIII also plays a role in many cancers. Increased expression of TGF beta RIII is found in higher grade lymphomas, and reduced expression of TGF beta RIII is found with advanced stage neuroblastomas and ovarian carcinomas (4, 7 - 9). Low TGF-beta RIII expression also correlates with higher grade among a cohort of breast cancers (4, 10). Additionally, overexpression of TGF-beta RIII in MDA-231 human breast cancer cells and DU145 prostate cancer cells results in decreased tumor invasion in vitro and in vivo (4, 11 - 12).
![Immunocytochemistry Endoglin/CD105 Antibody [Unconjugated]](https://images.novusbio.com/images2/Endoglin_AF1320_Immunocytochemistry_7258.jpg)
![Immunocytochemistry Endoglin/CD105 Antibody [Unconjugated]](https://images.novusbio.com/images2/Endoglin_AF1320_Immunocytochemistry_12779.jpg)
![Simple Western Endoglin/CD105 Antibody [Unconjugated]](https://images.novusbio.com/images2/Endoglin_AF1320_Simple_Western_18976.jpg)
![Simple Western Decorin Antibody [Unconjugated]](https://images.novusbio.com/images2/Decorin_AF1060_Simple_Western_18969.jpg)
![Western Blot Decorin Antibody [Unconjugated]](https://images.novusbio.com/images2/Decorin_AF1060_Western_Blot_19006.jpg)
![Immunohistochemistry Decorin Antibody [Unconjugated]](https://images.novusbio.com/images/af1060_mouse-decorin-affinity-purified-polyclonal-ab-8120255552891.jpg)
![Western Blot TGF-beta RII Antibody [Unconjugated]](https://images.novusbio.com/images2/TGFbeta_RII_AF241NA_Western_Blot_21284.jpg)
![Neutralization TGF-beta RII Antibody [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_RII_AF-241-NA_Block_Neutralize_8662.jpg)
![Immunohistochemistry TGF-beta RII Antibody [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_RII_AF-241-NA_Immunohistochemistry_9941.jpg)
|
TGF-beta RIII - a high affinity reservoir for TGF-beta I/II ligands with therapeutic potential TGF beta (transforming growth factor beta) is a superfamily of cytokines that participate in a variety of cellular processes including growth, proliferation, differentiation, and apoptosis. There are 3 classes of receptors for TGF beta cytokines an... Read full blog post. |
|
TGF-beta RIII - A multi-functional regulator of the TGF-beta signaling pathway Transforming growth factor-beta receptor III (TGF-beta RIII) is one of three receptors for the secreted growth factor TGF-beta. Unlike type I and type II TGF-beta receptors, TGF-beta RIII does not participate directly in the propagation of intracel... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Western Blot TGF-beta RI/ALK-5 Antibody [Unconjugated]](https://images.novusbio.com/images2/TGFbeta_RI_AF3025_Western_Blot_17081.jpg)
![Immunocytochemistry TGF-beta RI/ALK-5 Antibody [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_RI_AF3025_Immunocytochemistry_9948.jpg)
![Western Blot TGF-beta RI/ALK-5 Antibody [Unconjugated]](https://images.novusbio.com/images/af3025_human-tgf-beta-ri-alk-5-affinity-purified-polyclonal-ab-41202412402510.jpg)
![Bioactivity TGF-beta 1 [Unconjugated]](https://images.novusbio.com/images/protein/7754-bhcf_recombinant-human-tgf-beta-1-human-cell-expressed-cf-bioactivity-1811202013946.jpg)
![SDS-PAGE TGF-beta 2 [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_2_302-B2_268.jpg)
![Bioactivity TGF-beta 2 [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_2_302-B2_269.jpg)
![Western Blot Smad2/3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Smad3_AF3797_Western_Blot_5347.jpg)
![Chromatin Immunoprecipitation (ChIP) Smad2/3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Smad3_AF3797_Chromatin_Immunoprecipitation_11240.jpg)
![Immunocytochemistry Smad2/3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Smad3_AF3797_Immunocytochemistry_11829.jpg)
![Bioactivity CTLA-4 [Unconjugated]](https://images.novusbio.com/images2/CTLA4_7268CT_2293.jpg)
![Bioactivity TGF-beta 3 [Unconjugated]](https://images.novusbio.com/images/243-b3_recombinant-human-tgf-beta-3-protein-bioactivity-1342023172157.jpg)